PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRiferminogene pecaplasmid
Riferminogene pecaplasmid
Riferminogene pecaplasmid is a gene pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peripheral arterial diseaseD058729EFO_0004265213
Peripheral vascular diseasesD016491EFO_0003875I73.9112
IschemiaD007511EFO_000055611
Vascular diseasesD014652EFO_0004264I7711
Chronic limb-threatening ischemiaD00008980211
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Arterial occlusive diseasesD001157EFO_00090852215
Intermittent claudicationD007383EFO_0003876I73.911
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRiferminogene pecaplasmid
INNriferminogene pecaplasmid
Description
Riferminogene pecaplasmid is a gene pharmaceutical. It is currently being investigated in clinical studies.
Classification
Gene
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108293
ChEBI ID
PubChem CID
DrugBank
UNII ID3G30P7ME1J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use